Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741567 | 0.96 | APP (0.46) | ACHEMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL13967517 | 0.93 | PTGS2 (0.46) | MEN1KMT2ANFE2L2PTGS2APP | |
| SCHEMBL10018702 | 0.91 | PTGS2 (0.48) | ACHENFE2L2PTGS2APPPDE3B | |
| SCHEMBL2810519 | 0.89 | PTGS1 (0.46) | ACHEMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL10013948 | 0.89 | PTGS2 (0.47) | ACHENFE2L2PTGS2APPCYP3A4 | |
| SCHEMBL14206975 | 0.88 | ACHE (0.52) | ACHEMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL12011033 | 0.88 | ACHE (0.52) | ACHEMEN1KMT2ANPC1ALOX15 | |
| SCHEMBL803426 | 0.87 | PDE3B (0.48) | ACHENFE2L2PTGS2APPDHODH | |
| SCHEMBL1046583 | 0.87 | ACHE (0.50) | ACHEMEN1KMT2ANFE2L2PTGS2 | |
| SCHEMBL17110104 | 0.85 | ACHE (0.48) | ACHEMEN1KMT2ANFE2L2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043782-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2024-07-23 | — | — | US | disclosed |
| US-12043782-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2024-07-23 | — | — | US | disclosed |
| WO-2024017812-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-01-25 | — | — | WO | disclosed |
| EP-4279565-A2 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3980510-B1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3679111-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795398-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same and compounds | MERCK PATENT GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11788009-B2 | Liquid-crystalline medium for use in a switching element | MERCK PATENT GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-11788009-B2 | Liquid-crystalline medium for use in a switching element | MERCK PATENT GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-20120032112-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-02-09 | — | — | US | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399584-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010089092-A1 | LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2010-08-12 | — | — | WO | disclosed |
| EP-1713880-B1 | LIQUID CRYSTAL MATERIALS | DOW CORNING (US) | 2009-10-28 | — | — | EP | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| EP-2100944-A1 | Liquid crystal medium and liquid crystal display | MERCK PATENT GmbH (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | AK1, IRAK1, CNKSR1 | ACHE 1753/4885MEN1 2686/4885KMT2A 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.